Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients

European Journal of Medical Research

Volumn 12, Issue 3, 2007, Pages 93-102

  Salzberger, Bernd ^a   Daumer M ^b   Gute, P ^c   Jaeger, H ^d   Knechten, H ^e   Van Lunzen, J ^f   Mauss, S ^g   Mayr, C ^h   Moll, A ⁱ   Plettenberg, A ^j   Rockstroh, J ^k   Staszewski, S ^l   Stellbrink, H J ^m   Stoll, M ⁿ   Sturmer, M ^l  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Gemeinschaftspraxis Gute Locher Lutz   (Germany)

^d HIV Research and Clinical Care Centre Munich   (Germany)

^e Praxen Zentrum Blondelstrasse   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g Center for HIV and Hepatogastroenterology   (Germany)

^h Practice Aerzteforum Seestraße   (Germany)

ⁱ Praxiszentrum Kaiserdamm   (Germany)

^j Ifi Institute for Interdisciplinary Infectiology   (Germany)

^k UNIVERSITY OF BONN   (Germany)

^l UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^m Gemeinschaftspraxis   (Germany)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MK 0518; NEVIRAPINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ALGORITHM; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL FUSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INJECTION SITE REACTION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PREGNANCY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ALGORITHMS; CLINICAL TRIALS, PHASE III; DRUG RESISTANCE, VIRAL; GERMANY; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PATIENT EDUCATION; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34147189691     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Haubrich R. DeMasi R, Thommes J et al. Improved Virologic Response in Three-Class Experienced Patients When an Active Boosted Protease Inhibitor Is Combined with Enfuvirtide (ENF). Abstract 785, 43rd IDSA 2005, San Francisco.
2. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA. 2006 Aug 16;296(7):827-43.
3. Bartlett JA, Fath MJ, DeMasi R et al. An updated systematic overview of triple combination therapy in antiretroviral-naïve HIV-infected adults. AIDS. 2006 Oct 24;20(16): 2051-64.
4. Hogg RS, Bangsberg DR, Lima VD et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006 Sep;3(9):e356.
5. Little SJ, Holte S, RoutyJP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002 Aug 8;347(6):385-94.
6. Markowitz M, Mohri H, Mehandru S et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet. 2005 Mar 19-25;365(9464):1031-8.
7. Vandamme AM, Sonnerborg A, Ait-Khaled M et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther. 2004 Dec;9(6):829-48.
8. Harrigan PR, Wynhoven B, Brumme Zl et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis. 2005 Apt 15;191(8):1325-30. Epub 2005 Mar 16.
9. Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD; Terry Beirn. Community Programs for Clinical Research on AIDS; Canada HIV Trials Network. CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis. 2005 Oct 15;192(8):1407-11. Epub 2005 Sep 9.
10. Matthews T, Salgo M, Greenberg M et al. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4-1ymphocytes. Nat Rev Drug Discov. 2004 Mar;3(3): 215-25. Review.
11. Delfraissy J-F, Montaner J, Eron J et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviral (ARV) treatment-experienced patients. Abstract 568, 10th CROI 2003, Boston.
12. Nelson M, Arasteh K, Clotet B et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment experienced HIV-1 infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Aquir Immune Defic Syndr. 2005;40:404-412.
13. Arasteh K, Lazzarin A, Clotet B et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regime. Abstract MoOrB1058, Proceedings of the XV International AIDS Conference. 2004;197-201.
14. Cooper D, Hicks C, Cahn P et al. 24-Week RESIST Study Analyses: the Efficacy of Tipranavir/Ritonavir Is Superior to Lopinavir/Ritonavir, and the TPV/r Treatment Response is Enhanced by Inclusion of Genotypically Active Antiretrovirals in the Optimized Background Regimen. Abstract 560, 12th CROI 2005, Boston.
15. Hicks CB, Cahn P, Cooper DA et al. (the RESIST Investigator Group). Durable efficacy of tipranavir/ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006 Aug 5;368(9534):466-75.
16. Youle M, Staszweski S, Clotet B et al. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV Clin Trials. 2006 Mar-Apr;7(2):86-96.
17. Grinsztejn, B, Nguyen, B-Y. Katlama, C et al. Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus: 24 Week Data. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract H-1670b, 46th ICAAC 2006, San Francisco.
18. Svicher V, Aquaro S, D'Arrigo R et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1 infected patients receiving enfuvirtide treatment. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monte Carlo, Monaco, Reviews in Antiviral Therapy 2: 35.
19. Melby T, DeSpirito M, DeMasi R et al. Impact of enfuvirtide resistance genotype on CD4 increases in patients with ongoing viral replication while receiving enfuvirtide. Antiviral Therapy 2006; 11: S43
20. Montaner J, Chung J, Guimaraes D et al. A treatment staging proposal derived from a post hoc analysis of the 48 week results from the TORO studies. Abstract Tu-PeeB4483, 15th International AIDS Conference 2004, Bangkok.
21. Witek J, Rockstroh J, Donatacci L et al. Adherence to Enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy. Abstract WePeB5822, 15th International AIDS Conference 2004, Bangkok.
22. Home R, Cooper V, Tsoukas C et al. Injectable therapy in HIV: the role of physician and patient attitudes. Abstract WePe0268, 16th International Aids Conference 2006, Toronto
23. Youle M, Arastéh K, Clotet B et al. et al. Potential Barriers and Motivators to Enfuvirtide Use: Physician Perspectives of Injectable Antiretrovirals (ARVs). Abstract PE7.3/24, 10th EACS 2005, Dublin.
24. Horne R, Clotet B, Cohen C et al. Treatment-Experienced Patient's Perceptions of Self-Injectable Therapy. Abstract PE7.3/25, 10th EACS 2005, Dublin.
25. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - October 10, 2006. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf (accessed 3 Nov 2006).
26. Recommandations du groupe d'experts sous la direction du Professeur Patrick Yeni réalisé avec le soutien du Ministère de la Santé et des Solidarités. Prise en charge médicale des personnes infectées par le VIH. 2006: 46
27. Rachlis A, Angel J, Harris M et al. Canadian consensus recommendations for the optimal use of enfuvirtide in HIV/AIDS patients. Can J Infect Dis med Microbiol 2006;17(3):155-163.
28. Bartlett JA, Salgo M, DeMasi R. Early viral load responses on Enfuvirtide in heavily treatment-experienced patients. Abstract TuPeB4484, 15th International Aids Conference 2004, Bangkok.
29. Raffi F, Katlama C, Saag M et al. Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regime Only (TORO) Trials. CID 2006: 42. 870-877.
30. Sweeney E, Johnson N, DeSpirito M et al. Positive patient adherence and satisfaction using a novel nursing support program as part of enfuvirtide therapy. Abstract TuPe0152, 16th International Aids Conference 2006, Toronto.
31. Eron J Delfraissy J, Kuritzkes D, et al. et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials., Abstract H-836, 43rd ICAAC 2003, Chicago.
32. Barretina J, Blanco J, Bonjoch A et al. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS. 2004 Aug 20;18(12):1673-82.
33. FUZEON, Summary of Product Characteristics. April 2005.
34. Meyohas M-C, Lacombe K, Morand-Joubert L, Girard P-M. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS. 2004 Sep 24;18(14):1966-8.
35. Cohan D, Feakins C, Wara D et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS. 2005 Jun 10;19(9):989-90.
36. Brennan-Benson P, Pakianathan M, Rice P et al. Enfuvirtide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS. 2006 Jan 9;20(2):297-9.
37. Wensing AM, Boucher CA, van Kasteren M et al. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 2006 Jun 26;20(10):1465-7.
38. Oette M, Kaiser R, Daumer M et al. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res. 2004 May 28;9(5):273-8.
39. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004 May;78(9):4628-37.
40. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004 Aug;54(2):333-40. Epub 2004 Jul 1. Review.
41. Aquaro S, Svicher V, Arrigo RD et al. Characterization of GP41 Evolution in a Large Cohort of HIV-1-infected Patients Receiving Long-term T-20 Treatment as a single Active Drug. Abstract 596, 13th CROI 2006, Denver.
42. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 1;192(9):1537-44. Epub 2005 Sep 20.